WOCKHARDT LTD. - 532300 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Wockhardt Limited has informed the stock exchange regarding a press release dated June 28, 2024 titled "Successful use of investigational antibiotic Zaynich (Zidebactam/Cefepime -WCK 5222) to treat a cancer patient in US with chronic bilateral thigh infection caused by an extreme drug resistant Pseudomonas." WOCKHARDT LTD. - 532300 - Shareholder Meeting / Postal Ballot-Outcome of AGM
Wockhardt Ltd has informed Pursuant to Regulation 30 of SEBI Listing Regulations regarding proceeding of the Annual General Meeting held today i.e. June 28, 2024 WOCKHARDT LTD. - 532300 - Closure of Trading Window
This is to inform you that pursuant to Company''s Code of Conduct for regulating, monitoring and reporting trading by designated persons, the Trading window for dealing in equity shares of the company will be closed from 1st July, 2024 until 48 hours after the declaration of unaudited financial results of the company for the quarter ended 30th June, 2024. WOCKHARDT LTD. - 532300 - Announcement under Regulation 30 (LODR)-Change in Management
Change in Senior Management Personnel WOCKHARDT LTD. - 532300 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find enclosed herewith newspaper extract of public notice issued by the Company pertaining to the 25th AGM of the Company. WOCKHARDT LTD. - 532300 - Record Date For The Purpose Of 25Th Annual General Meeting Of Of Wockhardt Limited Scheduled To Be Held On Friday, 28Th June, 2024 At 11:00 Am (IST), Through Video Conferencing (VC)/ Other Audio Visual Means (OAVM)
The Record date for the purpose of 25th AGM of Wockhardt Limited shall be Friday, 21st June, 2024. WOCKHARDT LTD. - 532300 - Business Responsibility and Sustainability Reporting (BRSR)
Business Responsibility and Sustainability Report for the Financial Year ended 31st March, 2024. WOCKHARDT LTD. - 532300 - Reg. 34 (1) Annual Report.
Annual Report of the Company for the Financial Year 2023-24 WOCKHARDT LTD. - 532300 - Notice Of 25Th Annual General Meeting And The Annual Report Of The Company For The Financial Year 2023-24
The 25th Annual General Meeting of the Members of Wockhardt Limited will be held on Friday, 28th June, 2024 at 11:00 a.m. (IST), through Video Conferencing (VC) / Other Audio Visual Means (OAVM). Q4FY24 Quarterly & FY24 Annual Result Announced for Wockhardt Ltd.
Pharmaceuticals company Wockhardt announced Q4FY24 & FY24 results: YoY growth of 7% in revenue in FY24, Revenue for FY24 of Rs 2,879 crore compared to Rs 2,693 crore in the previous year. QoQ growth of 6%, Revenue for the quarter being Rs 750 crore compared to Rs 710 crore in Q4FY23. YoY growth of 74% in EBITDA in FY24, EBITDA for FY24 at Rs 251 crore compared to Rs 144 crore in the previous year. Quarterly growth in EBITDA by 49% compared to the previous year, EBITDA for Q4FY24 at Rs 70 crore compared to Rs 47 crore in Q4FY23. UK Business stood at Rs 268 crore in Q4FY24 compared to Rs 242 crore in Q4FY23 registering a growth of 11% and contributed about 36% of Global Revenue in the current quarter. UK Business stood at Rs 1,041 crore in FY24 compared to Rs 887 crore in FY23 registering a growth of 17% and contributed about 36% of Global Revenue in FY24. Emerging Markets Business of the Company stood at Rs 190 crore in Q4FY24 contributing to about 25% of the Global Revenue. Emerging Markets Business stood at Rs 642 crore in FY24 compared to Rs 555 crore in FY23 registering a growth of 16% and contributing to about 22% of the Global Revenue. Irish Business stood at Rs 45 crore in Q4FY24 compared to Rs 44 crore in Q4FY23 registering a growth of 4%. Irish Business stood at Rs 179 crore in FY24 compared to Rs 158 crore in FY23 registering a growth of 13%. India Business stood at Rs 181 crore in Q4FY24 compared to Rs 125 crore in the previous year registering a growth of 45%. India business stood at Rs 641 crore compared to Rs 609 crore in FY23 registering a growth of 5% and contributing to 22% of the Global Revenue in FY24. US Business stood at Rs 42 crore in Q4FY24 contributing 6% of the Global Revenue. US Business stood at Rs 175 crore in FY24 contributing 6% of the Global Revenue. Result PDF